Some of the rest was rather weak, like FoB's and pathetic like M118.
I am not sure that I would be quite that negative - e.g. they talked about restarting M118 partnering discussions because the environment has changed in cardiac drugs. But I wouldn't rate it as positively as many of the other posters on this board.
What really surprised me is that CW refused to comment on any M&A activity - which would seem to be an implicit acknowledgement that it is on the table since certainly there are companies that do publicly disavow any interest in a merger as part of partnering.
Market Data 
Markets 
AI
